TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06775483: Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 220 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06775483 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06775483 Rescue Dossier →